Agios Q3 2026 Results: Mitapivat Revenue Surpasses 2025 Total
Agios reported third-quarter 2026 net revenues of $55.4 million, driven by strong U.S. demand for AQVESME and the European launch of mitapivat, effectively outperforming its 2025 total in just three months.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed